Rapid Molecular Assay Detects Pneumonia Causative Agents
|
By LabMedica International staff writers Posted on 16 May 2012 |
A rapid real-time polymerase chain reaction assay (qPCR) has been developed for detecting two microrganisms that cause pneumonia directly from respiratory specimens.
The assay provides over five times faster results compared to existing methods while maintaining equivalent detection rates for specimens containing limited target organisms such as Mycoplasma pneumoniae and Chlamydophila (Chlamydia) pneumoniae.
Scientists the Respiratory Diseases Branch, of the US Centers for Disease Control and Prevention (CDC; Atlanta, GA, USA) developed and evaluated individual singleplex assays for each pathogen and a multiplex assay for simultaneous detection of M. pneumoniae, C. pneumoniae, and human DNA. Nasopharyngeal and/or oropharyngeal clinical specimens were collected by the Centers for Disease Control and Prevention during domestic outbreaks between 2007 and 2009.
Primers and probes previously designed and optimized for specific detection of the ATPase Mp3 for M. pneumoniae, the arginine repressor (argR) of C. pneumoniae, and human nucleic acid (RNase P) were used in the study. For singleplex reactions, the reaction mix contained PerfeCTa qPCR FastMix and for multiplex reactions the PerfeCTa Multiplex qPCR SuperMix was used, and both are products of Quanta Biosciences, (Gaithersburg, MD, USA). Total nucleic acid (TNA) was extracted from universal transport media (UTM) using a Nucleic Acid Isolation Kit I on the MagNA Pure Compact instrument (Roche Applied Science, Indianapolis, IN, USA).
The scientists found a greater than 90% concordance using the rapid singleplex or multiplex assay. They then assessed the performance of the rapid real-time PCR assay using UTM directly from clinical specimens without nucleic acid extraction. Of the specimens identified as positive by standard real-time PCR, 90% and 59% of UTM samples were positive for M. pneumoniae and C. pneumoniae, respectively, using singleplex assays. These percentages dropped to 69% for M. pneumoniae and 52% for C. pneumoniae when tested with the rapid multiplex assay.
The authors concluded that although some loss of sensitivity was observed when performing rapid real-time PCR without a separate extraction step, this method may still be a valuable tool for identification of M. pneumoniae and C. pneumoniae infections in the primary care setting that would otherwise go unnoticed or misdiagnosed. Point-of-care testing would likely improve patient treatment, reduce inappropriate antibiotic use, and have utility for rapid pathogen detection in situations where prompt results are critical. The study was published on April 25 2012 in the journal Diagnostic Microbiology and Infectious Disease.
Related Links:
US Centers for Disease Control and Prevention
Quanta Biosciences
Roche Applied Science
The assay provides over five times faster results compared to existing methods while maintaining equivalent detection rates for specimens containing limited target organisms such as Mycoplasma pneumoniae and Chlamydophila (Chlamydia) pneumoniae.
Scientists the Respiratory Diseases Branch, of the US Centers for Disease Control and Prevention (CDC; Atlanta, GA, USA) developed and evaluated individual singleplex assays for each pathogen and a multiplex assay for simultaneous detection of M. pneumoniae, C. pneumoniae, and human DNA. Nasopharyngeal and/or oropharyngeal clinical specimens were collected by the Centers for Disease Control and Prevention during domestic outbreaks between 2007 and 2009.
Primers and probes previously designed and optimized for specific detection of the ATPase Mp3 for M. pneumoniae, the arginine repressor (argR) of C. pneumoniae, and human nucleic acid (RNase P) were used in the study. For singleplex reactions, the reaction mix contained PerfeCTa qPCR FastMix and for multiplex reactions the PerfeCTa Multiplex qPCR SuperMix was used, and both are products of Quanta Biosciences, (Gaithersburg, MD, USA). Total nucleic acid (TNA) was extracted from universal transport media (UTM) using a Nucleic Acid Isolation Kit I on the MagNA Pure Compact instrument (Roche Applied Science, Indianapolis, IN, USA).
The scientists found a greater than 90% concordance using the rapid singleplex or multiplex assay. They then assessed the performance of the rapid real-time PCR assay using UTM directly from clinical specimens without nucleic acid extraction. Of the specimens identified as positive by standard real-time PCR, 90% and 59% of UTM samples were positive for M. pneumoniae and C. pneumoniae, respectively, using singleplex assays. These percentages dropped to 69% for M. pneumoniae and 52% for C. pneumoniae when tested with the rapid multiplex assay.
The authors concluded that although some loss of sensitivity was observed when performing rapid real-time PCR without a separate extraction step, this method may still be a valuable tool for identification of M. pneumoniae and C. pneumoniae infections in the primary care setting that would otherwise go unnoticed or misdiagnosed. Point-of-care testing would likely improve patient treatment, reduce inappropriate antibiotic use, and have utility for rapid pathogen detection in situations where prompt results are critical. The study was published on April 25 2012 in the journal Diagnostic Microbiology and Infectious Disease.
Related Links:
US Centers for Disease Control and Prevention
Quanta Biosciences
Roche Applied Science
Latest Microbiology News
- TORCH Infection Trends Point to Need for Tailored Screening in Pregnancy
- Automated Blood Culture System Speeds Detection of Bloodstream Infections
- New Culture Medium Speeds C. difficile Resistance Detection and Reduces Costs
- Gut Microbiome Signatures Help Identify Risk of IBD Progression
- FDA-Cleared Gastrointestinal Panel Detects 24 Pathogen Targets
- New AMR Assay Supports Rapid Infection Control Screening in Hospitals
- Diagnostic Gaps Complicate Bundibugyo Ebola Outbreak Response in Congo
- Study Finds Hidden Mpox Infections May Drive Ongoing Spread
- Large-Scale Genomic Surveillance Tracks Resistant Bacteria Across European Hospitals
- Molecular Urine and Stool Tests Do Not Improve Early TB Treatment in Hospitalized HIV Patients
- Rapid Antigen Biosensor Detects Active Tuberculosis in One Hour
- Label-Free Microscopy Method Enables Faster, Quantitative Detection of Malaria
- Oral–Gut Microbiome Signatures Identify Early Gastric Cancer
- Gut Microbiome Test Predicts Melanoma Recurrence After Surgery
- Rapid Blood-Culture Susceptibility Panel Expands Coverage for Gram-Negative Infections
- Antibiotic Resistance Genes Found in Newborns Within Hours of Birth
Channels
Clinical Chemistry
view channel
Simple Blood-Based Cholesterol Efflux Assay Identifies High-Risk Coronary Plaque Features
Unstable coronary plaques are difficult to identify before they trigger acute cardiovascular events. Standard high-density lipoprotein (HDL) measurements do not always capture how well HDL particles function... Read more
Plasma Vitamin C Levels Associated with Brain Structure and Connectivity in Aging
Previous studies have linked vitamin C–rich diets with lower risk of cognitive impairment in older adults. However, few investigations have directly examined blood plasma vitamin C in relation to brain... Read more
Mass Spectrometry Detects Tumor Metabolites for Cancer Monitoring
Cancer’s altered metabolism complicates how clinicians detect and monitor tumors, because nutrient use can shift with context and time. Measuring small-molecule metabolites that distinguish malignant from... Read more
Urinary Biomarker Assay Predicts Kidney Disease Progression Beyond Standard Measures
Many patients with type 2 diabetes and chronic kidney disease continue to experience progressive renal decline, yet conventional markers such as albuminuria and estimated glomerular filtration rate (eGFR)... Read moreMolecular Diagnostics
view channel
Ultrasensitive HPV Blood Test Predicts Early Recurrence in Head and Neck Cancer
Human papillomavirus (HPV)-associated head and neck cancers are frequently treated with surgery, but some patients experience recurrence due to residual microscopic disease. Postoperative decisions about... Read more
New Library Normalization and Amplification Tools Support Oncology Sequencing
High-throughput next-generation sequencing (NGS) laboratories continue to grapple with uneven library pooling and amplification artifacts that can degrade variant calling accuracy and increase reruns.... Read moreHematology
view channel
Next-Generation Hematology Platform Streamlines High-Complexity Lab Workflows
Sysmex America (Chicago, IL, USA) has introduced the next generation XR-Series, centered on the XR-10 Automated Hematology Module for high-complexity laboratories. The platform builds on the widely used... Read more
Blood Eosinophil Count May Predict Cancer Immunotherapy Response and Toxicity
Immune checkpoint inhibitors have improved outcomes across many cancers, yet only a subset of patients derive durable benefit and biomarkers to guide treatment remain limited. Eosinophils, best known for... Read moreImmunology
view channelAptamer-Based Biosensor Enables Mutation-Resilient SARS-CoV-2 Detection
Rapid evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can undermine existing molecular diagnostics, especially when assays target small viral components. Double-antibody sandwich... Read more
Study Points to Autoimmune Pathway Behind Long COVID Symptoms
Long COVID leaves many SARS-CoV-2 survivors with persistent fatigue, cognitive issues, palpitations, and musculoskeletal pain for months or years. Estimates cited in new research suggest 4%–20% of infected... Read more
Metabolic Biomarker Distinguishes Latent from Active Tuberculosis and Tracks Treatment Response
Tuberculosis (TB) remains the world’s leading infectious killer, with 10.8 million cases and 1.25 million deaths recorded globally in 2023. Yet many infected individuals never develop active disease, underscoring... Read morePathology
view channel
Uncertainty-Aware AI Platform Supports Automated HER2 Assessment in Breast Cancer
Accurate assessment of human epidermal growth factor receptor 2 (HER2) is critical for breast cancer diagnosis and treatment selection, yet scoring variability and infrastructure requirements can complicate... Read more
AI Tool Speeds Brain Tumor Classification from Routine Histology Slides
Accurate classification of brain and spinal cord tumors increasingly depends on molecular profiling alongside histology, but access to such testing remains limited and results can take about two weeks.... Read more
IHC Companion Diagnostic Standardizes Mismatch Repair Testing for Cancer Immunotherapy
Deficient DNA mismatch repair is an established predictive biomarker for response to immune checkpoint inhibitors, yet access to standardized assessment has varied across tumor types. Cancer remains the... Read moreTechnology
view channel
AI Platform Links Biomarker Results to Cancer Clinical Trials and Guidelines
Oncology teams must manage growing volumes of genomic data, rapidly evolving clinical trial options, and frequently updated care guidelines, all within tight clinic schedules. Translating complex tumor... Read more
Agentic AI Platform Supports Genomic Decision-Making in Oncology
Oncology care teams increasingly face the challenge of managing complex molecular diagnostics, evolving treatment options, and extensive electronic health record documentation. Translating multimodal data... Read moreIndustry
view channel
Open-Source Consortium Aims to Standardize Digital Pathology Workflows
Digital pathology is expanding rapidly as laboratories adopt whole-slide imaging and computational tools to meet growing diagnostic and biomarker-testing demand. However, fragmented software infrastructure... Read more








